New insights into the pathogenesis and treatment of anthrax toxin-induced shock

Expert Opinion on Biological Therapy

Volumn 7, Issue 6, 2007, Pages 843-854

  Li, Yan ^a   Sherer, Kevin ^a   Cui, Xizhong ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anthrax; Pathogenesis; Toxin; Treatment

Indexed keywords

ANTHRAX TOXIN; ANTIBIOTIC AGENT; CLINDAMYCIN; RIFAMPICIN;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; EDEMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; SHOCK;

ADENYLATE CYCLASE; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTORS, PEPTIDE; SHOCK, SEPTIC; VIRULENCE;

BACILLUS ANTHRACIS;

EID: 34250737810     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.6.843     Document Type: Review

References (114)

1. HOLTY JE, BRAVATA DM, LIU H et al.: Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann. Intern. Med. (2006) 144:270-280. • An important review of all anthrax cases reported on in the US over the past 100 years.
2. JERNIGAN JA, STEPHENS DS, ASHFORD DA: Bioterrorrissm-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. (2001) 7:933-944. • A comprehensive clinical review of 10 of the 11 inhalational anthrax cases presenting during the 2001 outbreak in the US.
3. SHERER K, LI Y, CUI X, EICHACKER PQ: Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am. J. Respir. Crit. Care Med. (2007) 175:211-221.
4. LEPPLA SH: Anthrax toxin. In: Bacterial Proteins. Aktories K, Just I (Eds), New York, NY: Springer (2000):445-472.
5. COLLIER RJ, YOUNG JA: Anthrax toxin. Ann. Rev. Cell Dev. Biol. (2003) 19:45-70.
6. XU L, FRUCHT DM: Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Int. J. Biochem. Cell Biol. (2007) 39:20-24.
7. RAINEY GJA, YOUNG JAT: Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. (2004) 2:721-726.
8. PETOSA C, COLLIER RJ, KLIMPEL KR et al.: Crystal structure of the anthrax toxin protective antigen. Nature (1997) 385:833-838.
9. BRADLEY KA, MOGRIDGE J, MOUREZ M et al.: Identification of the cellular receptor for anthrax toxin. Nature (2001) 414:225-229.
10. SCOBIE HM, RAINEY GJ, BRADLEY KA, YOUNG JA: Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA (2003) 100:5170-5174.
11. LACY DB, WIGELSWORTH DJ, SCOBIE HM et al.: Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA (2004) 101:6367-6372.
12. SCOBIE HM, WIGELSWORTH DJ, MARLETT JM et al.: Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog. (2006) 2(10):e111. • A report including references to other recent work directed at anthrax toxin and host cell receptor interactions.
13. GORDON VM, KLIMPEL KR, ARORA N et al.: Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. (1995) 63:82-87.
14. ABRAMI L, LIU S, COSSON P et al.: Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. (2003) 160:321-328.
15. CHEKANOV AV, REMACLE AG, GOLUBKOV VS et al.: Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Arch. Biochem. Biophys. (2006) 446:52-59.
16. MOGRIDGE J, CUNNINGHAM K, LACY DB et al.: The lethal and edema factors of anthrax toxin bind only to oligometic forms of the protective antigen. Proc. Natl. Acad. Sci. USA (2002) 99:7045-7048.
17. MOGRIDGE J, CUNNINGHAM K, COLLIER RJ: Stoichiometry of anthrax toxin complexes. Biochemistry (2002) 41:1079-1082.
18. WEI W, LU Q, CHAUDRY GJ et al.: The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell (2006) 124:1141-1154.
19. YOUNG JJ, BROMBERG-WHITE JL, ZYLSTRA C et al.: LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality from anthrax lethal toxin. PLoS Pathog. (2007) 3(3):e27.
20. RAINEY GJA, WIGELSWORTH DJ, RYAN PL, SCOBIE HM, COLLIER RJ, YOUNG JA: Receptor-specific requirements for anthrax toxin delivery into cells. Proc. Natl. Acad. Sci. USA (2005) 102:13278-13283.
21. PANNIFER AD, WONG TY, SCHWARZENBACHER R et al.: Crystal structure of the anthrax lethal factor Nature (2001) 414:229-233.
22. DUESBERY NS, WEBB CP, LEPPLA SH et al.: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 280:734-737. • An early work identifying lethal factor's actions and intracellular target.
23. SMITH H, KEPPIE J, STANLEY JL: The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo. Br. J. Exp. Pathol. (1955) 36:460-472.
24. STANLEY JL, SMITH H: Purification of Factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. (1961) 26:49-63.
25. ECKERT NJ, BONVENTRE PF: In vivo effects of B. anthracis culture filtrates. J. Infect. Dis. (1963) 112:226-232.
26. BEALL FA, DALLDORF FG: The pathogenesis of the lethal effect of anthrax toxin in the rat. J. Infect. Dis. (1966) 116:377-389.
27. FISH DC, KLEIN F, LINCOLN RE et al.: Pathophysiological changes in the rat associated with anthrax toxin. J. Infect. Dis. (1968) 118:114-124.
28. VICK JA, LINCOLN RE, KLEIN F et al.: Neurological and physiological responses of the primate to anthrax toxin. J. Infect. Dis. (1968) 118(1):85-96.
29. CUI X, MOAYERI M, LI Y et al.: Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 286:R699-R709.
30. CUI X, LI Y, MOAYERI M et al.: Late treatment with a protective antigen derived monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J. Infect. Dis. (2005) 191:422-434.
31. HANNA PC, ACOSTA D, COLLIER RJ: On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA (1993) 90:10198-10201.
32. BALDARI CT, TONELLO F, PACCANI SR, MONTECUUCO C: Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. (2006) 27(9):434-440. • A review summarizing recent work on the potential immunosuppressive effects of anthrax toxins.
33. PELLIZZARI R, GUIDI-RONTANI C, VTTALE G et al.: Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNF. FEBS Lett. (1999) 462:199-204. • One of the first in vitro suides to show that lethal factor can suppress elements of the host innate immune response.
34. ERWIN JL, DASILVA LM, BAVARI S et al.: Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect. Immun. (2001) 69:1175-1177.
35. DANG O, NAVARRO L, ANDERSON K, DAVID M: Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J. Immunol. (2004) 172:747-751.
36. + T cells. J. Immunol. (2005) 174:4966-4971.
37. AGRAWAL A, LINGAPPA J, LEPPLA SH et al.: Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature (2003) 424:329-334.
38. MOAYERI M, HAINES D, YOUNG HA, LEPPLA SH: Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. (2003) 112:670-682. • The first in vivo studies demonstrating that lethality associated with anthrax lethal toxin is not associated with excessive inflammatory cytokine release.
39. CUI X, LI Y, LI X et al.: Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J. Infect. Dis. (2006) 193(6):829-840. • The initial in vivo study showing that anthrax lethal toxin can inhibit the host inflammatory response to both noninfectious and infectious stimuli.
40. KIRBY JE: Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. (2004) 72:430-439. • One of the first studies to demonstrate the direct effects lethal toxin might have on endothelial cells.
41. WARFEL JM, STEELE AD, D'AGNILLO F: Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. (2005) 166:1871-1881.
42. GOZES Y, MOAYERI M, WIGGINS JF, LEPPLA SH: Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect. Immun. (2006) 74:1266-1272.
43. CULLEY NC, PINSON DM, CHAKRABARTY A et al.: Pathological manifestations in mice exposed to anthrax lethal toxin. Infect. Immun. (2005) 73:7006-7010.
44. MOAYERI M, WEBSTER JI, WIGGINS JF et al.: Endocrine perturbation increases susceptibility to anthrax lethal toxin. Infect. Immun. (2005) 73:4238-4244.
45. BOYDEN ED, DIETRICH WF: Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. (2006) 38:240-244.
46. POPOV SG, VILLASMIL R, BERNARDI J et al.: Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. (2002) 293:349-355.
47. PARK JM, GRETEN FR, LI Z, KARIN M: Macrophage apoptosis by anthrax lethal factor through p38 inhibition. Science (2002) 297:2048-2051.
48. WRIGHT GC, MANDELL GI: Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. Med. (1986) 164:1700-1709.
49. DURING RL, LI W, HAO B et al.: Anthrax lethal toxin paralyzes neutrophil actin-based motility. J. Infect. Dis. (2005) 192:837-845.
50. CRAWFORD MA, AYLOTT CV, BOURDEAU RW, BOKOCH GM: Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. (2006) 176:7557-7565.
51. PACCANI SR, TONELLO F, GHITTONI R et al.: Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. (2005) 201:325-331.
52. COMER JE, CHOPRA AK, PETERSON JW, KONIG R: Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect. Immun. (2005) 73:8275-8281.
53. ROSSI PACCANI S, TONELLO F, PATRUSSI L et al.: Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microbiol. (2006) Epub ahead of print.
54. FANG H, XU L, CHEN TY et al.: Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J. Immunol. (2006) 176:6155-6161.
55. GUIDI-RONTANI C, WEBER-LEVY M, MOCK M, CABIAUX V: Translocation on B. anthracis lethal and oedema factors across endosome membranes. Cell Microbiol. (2000) 2:259-264.
56. NEUMEYER T, TONELLO F, DAL MOLIN F et al.: Anthrax edema factor, voltage-dependent binding to the protective antigen ion channel and comparison to LF binding. J. Biol. Chem. (2006) 281(43):32335-32343.
57. LACY DB, MOUREZ M, FOUASSIER A, COLLIERS RJ: Mapping the anthrax protective antigen binding site on the lethal and edema factors. J. Biol. Chem. (2002) 277:3006-3010.
58. LEPPLA SH: Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA (1982) 79:3162-3166. • The initial in vitro study demonstrating the adenyl cyclase activity of anthrax edema factor.
59. DAL MOLIN F, TONELLO F, LADANT D et al.: Cell entry and cAMP imaging of anthrax edema toxin. EMBO J. (2006) 25:5405-5413.
60. SHEN Y, ZHUKOVSKAYA NL, GUO Q et al.: Calcium-independant calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J. (2005) 24:929-941.
61. AHUJA N, KUMAR P, BHATNAGAR R: The adenylate cyclase toxins. Crit. Rev. Microbiol. (2004) 30:187-196.
62. KUMAR P, AJUJA N, BHATNAGAR R: Anthrax edema toxin requires influx of calcium for inducing cyclic AMP Toxicity in target cells. Infect. Immun. (2002) 70:4997-5007.
63. MALDONADO-AROCHO FJ, FULCHER JA, BENHUR L, BRADLEY KA Anthrax edema toxin induces anthrax toxin receptor expression in moncyte-derived cells. Mol. Microbiol. (2006) 61:324-337.
64. HAMBLETON P, CARMAN JA, MELLING J: Anthrax: the disease in relation to vaccines. Vaccine (1984) 2:125-132.
65. FIROVED AM, MILLER GF, MOAYERI M et al.: Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. (2005) 167:1309-1320. • The first study to investigate the in vivo effects of highly purified preparations of anthrax edema toxin.
66. CUI X, LI Y, LI X et al.: B. Anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J. Infect. Dis. (2007) 195:572-580. • The first in vivo study to directly compare the hemodynamic effects of anthrax edema and lethal toxins alone and together.
67. MURRAY KJ: Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. (1990) 47:329-345.
68. KATZ AM: Signal transduction: receptors, coupling proteins, and second messengers. In: Physiology of the Heart. Philadelphia: Lippincott, Williams and Wilkins (2001):255-286.
69. TOURNIER J, QUESNEL-HELLMANN A, MATHIEU J et al.: Anthrax edema toxin cooperated with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. (2005) 174:4934-4941. • An important in vitro study examining the the immunosuppressive effects of anthrax edema and lethal toxins together.
70. KRAKAUER T, LITTLE SF, STILES BG: Bacillus anthracis edema toxin inhibits Staphylococcus aures enterotoxin B effects in vitro: a potential protein therapeutic? Infect. Immun. (2005) 73:7069-7073.
71. HOOVER DL, FRIEDLANDER AM, ROGERS LC et al.: Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect. Immun. (1994) 62:4432-4439.
72. O'BRIEN J, FRIEDLANDER A, DREIER T et al.: Effects of anthrax toxin components on human neutrophils. Infect. Immun. (1985) 47:306-310.
73. TANAKA M, HASEGAWA T, OKAMOTO A et al.: Effect of antibiotics on Group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob. Agents Chemother. (2005) 49:88-96.
74. BEEB E, ZHONG J, CLAGETT M et al.: Protection against inhalation anthrax-induced lethality by a human monoclonal antibody to protective antigen in rabbits and cynomologous monkeys [abstract B-33]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology (2003):47.
75. LI Y, CUI X, HALEY M et al.: Fluids have opposing effects on survival comparing lipopolysaccharide (LPS) and Bacillus anthracis lethal toxin (LeTx) challenge in rats. Am. J. Resp. Crit. Care. Med. (2005) 2:A39.
76. LI Y, CUI X, SU J et al.: Increases in blood pressure with norepinephrine improve survival with LPS but not lethal toxin challenge in rats. Am. J. Resp. Crit. Care Med. (2007) 4:A39.
77. MOHAMED N, CLAGETT M, LI J et al.: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. (2005) 73:795-802.
78. PETERSON JW, COMER JE, NOFFSINGER DM et al.: Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. (2006) 74:1016-1024.
79. SUBRAMANIAN GM, CRONIN PW, POLEY G et al.: A Phase I study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis. (2005) 41:12-20.
80. MAYNARD JA, MAASSEN CBM, LEPPLA SH et al.: Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. (2002) 20:597-601.
81. CHEN Z, MOAYERI M, ZHOU Y et al.: Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. (2006) 193:625-633.
82. MABRY R, RANI M, GEIGER R et al.: Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an fc region. Infect. Immun. (2005) 73:8362-8368.
83. SAWADA-HIRAI R, JIANG I, WANG F et al.: Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines (2004) 2:5.
84. WILD MA, XIN H, MARUYAMA T et al.: Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. (2003) 21:1305-1306.
85. VITALE L, BLANSET D, LOWY I et al.: Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. (2006) 74:5840-5847.
86. SINGH Y, KHANNA H, CHOPRA AP, MEHRA V: A dominant-negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin in vivo. J. Biol. Chem. (2001) 276:22090-22094.
87. SELLMAN BR, MOUREZ M, COLLIER RJ: Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science (2001) 292:695-697.
88. KARGINOV VA, NESTOROVICH EM, YOHANNES A et al.: Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. Antimicrob. Agents Chemother. (2006) 50:3740-3753.
89. BACKER MV, PATEL V, JEHNING BT et al.: Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob. Agents Chemother. (2007) 51:245-251.
90. SARAC MS, PEINADO JR, LEPPLA SH, LINDBERG I: Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect. Immun. (2004) 72:602-605.
91. JIAO GS, CREGAR L, WANG J et al.: Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc. Natl. Acad. Sci. USA (2006) 103:19707-19712.
92. MOAYERI M, WIGGINS JF, LINDMAN RE, LEPPLA SH: Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. (2006) 50:2658-2665.
93. ZHAO P, LIANG X, KALBFLEISCH J et al.: Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antibodies (2003) 12:129-135.
94. LIM N, KIM J, OH MS et al.: An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. (2005) 73:6547-6551.
95. MIN D, TANG W, MRKSICH M: Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat. Biotechnol. (2004) 22:717-723.
96. PANCHAL RG, HERMONE AR, NGUYEN TL et al.: Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. (2004) 11:67-72.
97. FORINO M, JOHNSON S, WONG TY et al.: Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA (2005) 102:9499-9504.
98. DELLAICA I, DONA M, TONELLO F et al.: Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. (2004) 5:418-422.
99. MOUREZ M, KANE RS, MOGRIDGE J et al.: Designing a polyvalent inhibitor of anthrax toxin. Nat. Biotechnol. (2001) 19:958-961.
100. JOSHI A, SAARAPH A, POON V et al.: Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid. Bioconjug. Chem. (2006) 17:1265-1269.
101. BASHA S, RAI P, POON V et al.: Polyvalent inhibitors of anthrax toxin that target host receptors. Proc. Natl. Acad. Sci. USA (2006) 103:13509-13513.
102. RAI P, PADALA C, POON V et al.: Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat. Biotechnol. (2006) 24:582-586.
103. KUZMIC P, CREGAR L, MILLIS SZ, GOLDMAN M: Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides. FEBS J. (2006) 273:3054-3062.
104. GOLDMAN ME, CREGAR L, NGUYEN D et al.: Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol. (2006) 6:8.
105. JIAO GS, SIMO O, NAGATA M et al.: Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease. Bioorg. Med. Chem. Lett. (2006) 16(19):5183-5189.
106. MOAYERI M, WICKLIFFE KE, WIGGINS JF, LEPPLA SH: Oxidized ATP protection against anthrax lethal toxin. Infect. Immun. (2006) 74:3707-3714.
107. HIRSH MI, MANOV I, COHEN-KAPLAN V, IANCU TC: Ultrastructural features of lymphocyte suppression induced by anthrax lethal toxin and treated with chloroquine. Lab. Invest. (2006) Dec 18: Epub ahead of print.
108. TONELLO F, SEVESO M, MARIN O et al.: Screening inhibitors of anthrax lethal factor. Nature (2002) 418:386.
109. TURK BE, WONG TY, SCHWARZENBACHER R et al.: The sttuctural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. (2004) 11:60-66.
110. SHEN Y, ZHUKOVSKAYA NL, ZIMMER MI et al.: Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA (2004) 101:3242-3247.
111. SOELAIMAN S, WEI BQ, BERGSON P et al.: Structure-based inhibitor discovery against adenyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. (2003) 278:25990-25997.
112. WALSH JL, PESIK N, QUINN CP et al.: A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. CID (2007) 44:968-971.
113. www.washingtonpost.com/wp-dyn/content/article/2006/06/19/ AR2006061901135_pf.html. Accessed August 10 (2006). ROSENWALD MS: US to buy anthrax treatment from HGS. Washington Post. June 20 (2006).
114. www.hhs.gov/news/press/2006pres/20060728.html-9k. Cangene Corp. Winnipeg, Manitoba.